GlassScriptPhysician profile
Anan A Faidi
NPI 1609840479
$34,229.21
in general payments reported to CMS, 2019-2025
54 companies · $2,290 in 2025
The $2,290 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $4,579 · 2021: $2,947 · 2022: $2,219 · 2023: $1,432 · 2024: $1,545 · 2025: $2,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,203 · Education: $42.50 · Entertainment: $21.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,202.86 |
| Education | $42.50 |
| Entertainment | $21.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $20,518.36 | 2019-2021 | |
| Novo Nordisk INC | $2,903.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,986.09 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,571.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $898.54 | 2019-2022 | |
| Amgen INC. | $635.64 | 2019-2025 | Tepezza, Evenity, Repatha |
| Radius Health, INC. | $568.56 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $549.18 | 2019-2025 | |
| Abbott Laboratories | $461.54 | 2019-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $433.19 | 2019-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $317.92 | 2021-2025 | Gvoke Hypopen |
| Almatica Pharma LLC | $316.93 | 2024-2025 | Teriparatide |
| Novartis Pharmaceuticals Corporation | $231.48 | 2022-2025 | |
| Becton, Dickinson and Company | $210.92 | 2020-2022 | |
| Antares Pharma, INC. | $199.06 | 2020-2024 | Xyosted |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $180.62 | 2021-2023 | Minimed 770g |
| Beta Bionics, INC. | $162.12 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Merck Sharp & Dohme LLC | $141.74 | 2019-2021 | |
| Ascend Therapeutics US, LLC | $127.32 | 2021 | |
| Dexcom, INC. | $120.38 | 2021-2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $110.42 | 2019-2025 | |
| Lifescan, INC. | $109.09 | 2020-2022 | |
| Glaxosmithkline, LLC. | $107.63 | 2025 | Arexvy, Shingrix |
| Genzyme Corporation | $105.00 | 2019 | |
| Ascendis Pharma Endocrinology INC | $99.17 | 2024-2025 | Yorvipath |
| Madrigal Pharmaceuticals | $97.76 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $88.39 | 2019-2023 | Strensiq |
| Horizon Therapeutics Plc | $86.10 | 2021-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $72.19 | 2021-2025 | |
| Abbvie INC. | $67.40 | 2019-2024 | |
| Amarin Pharma, INC. | $64.53 | 2019-2021 | |
| Recordati_rare_diseases_inc. | $62.79 | 2023 | Signifor Lar, Isturisa |
| Cequr Corporation | $62.07 | 2022-2025 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $57.97 | 2020-2021 | |
| Medtronic Minimed, INC. | $56.42 | 2019-2020 | |
| Embecta Corp. | $53.13 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Insulet Corporation | $38.47 | 2021-2025 | Omnipod |
| Halozyme INC | $27.22 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $25.20 | 2019 | |
| Shire North American Group INC | $24.96 | 2019 | |
| Companion Medical, INC. | $24.90 | 2020 | |
| Alvogen INC | $24.05 | 2025 | Teriparatide |
| Rhythm Pharmaceuticals, INC. | $23.74 | 2025 | Imcivree |
| Verity Pharmaceuticals INC. | $23.64 | 2024 | Tlando |
| Optos, INC. | $21.69 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Ascensia Diabetes Care US INC. | $20.56 | 2024 | |
| Nevro Corp. | $20.50 | 2022 | |
| Acerus Pharmaceuticals Corporation | $20.35 | 2021 | |
| Averitas Pharma INC. | $18.27 | 2023 | Qutenza |
| Astellas Pharma US INC | $17.67 | 2024 | Veozah |
| Amphastar Pharmaceuticals, INC. | $17.41 | 2025 | |
| Echosens North America, INC. | $16.29 | 2025 | Fibroscan |
| E.R. Squibb & Sons, L.L.C. | $15.52 | 2023 | Camzyos |
| Kyowa Kirin, INC. | $14.18 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anan Faidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.